Announcement on Convening the Q3 2025 Performance Briefing
Filed with SSE · · 2 pages · Chinese
Chengdu Olymvax Biopharmaceuticals Inc. on 6ix
Earlier from Chengdu Olymvax Biopharmaceuticals
- Announcement on the Repurchase and Cancellation of the First Batch of Class A Restricted Shares Granted under the 2023 Restricted Stock Incentive Plan, Capital Reduction, and Notification to Creditors
- Announcement on Equity Change of Shareholders with Over 5% Shares Reaching 1% Scale and Results of Shareholding Reduction
- Announcement on Voluntary Disclosure of Initiating Phase III Clinical Trial of the Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) and Enrolling the First Subject
- Announcement on Repurchase and Cancellation of the First Category Restricted Shares Initially Granted under the 2023 Restricted Stock Incentive Plan That Have Been Granted But Not Yet Released from Sales Restrictions
- Announcement on Progress in the Acquisition of Minority Shareholders' Stock Rights of a Holding Subsidiary
Later from Chengdu Olymvax Biopharmaceuticals
- Announcement on Tax Payment
- Announcement on Completion of Shareholding Reduction Plan for Senior Management Members and Results of Shareholding Reduction
- Announcement on Litigation Involved
- Announcement on Signing a Supplementary Agreement to the Market Promotion Service Agreement for Group A and Group C Meningococcal Polysaccharide Vaccine
- Announcement on Voluntary Disclosure of Obtaining the GMP Compliance Certificate from the Philippines
Follow Chengdu Olymvax Biopharmaceuticals into a list and get an email when it puts out news.
Follow Chengdu Olymvax Biopharmaceuticals